NEW YORK (GenomeWeb) – Molecular diagnostics firm Admera Health announced today that it has signed three deals that will expand the availability of its pharmacogenomics tests in Asia.

Under the first deal, Admera will gain access to the existing physician network of Angsana Molecular & Diagnostics Laboratory, a molecular diagnostic assay developer with offices in Singapore, Hong Kong, and Malaysia. Under the other two deals, South Korea-based Biois and Taiwan-based AllBio Pharma will distribute Admera's full product portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.